MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.oraloncology.2017.07.022

Медицинская библиотека · Oral oncology · 2017

A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.

Nakano Kenji, Marshall Shoko, Taira Shinichiro, Sato Yukiko, Tomomatsu Junichi, Sasaki Toru, Shimbashi Wataru, Fukushima Hirofumi, Yonekawa Hiroyuki, Mitani Hiroki, Kawabata Kazuyoshi, Takahashi Shunji

Сравнительное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The effectiveness of the combination chemotherapy of weekly paclitaxel and cetuximab has not yet been compared to that of the current standard regimen, EXTREME (combination of 5-fluorouracil, cisplatin and cetuximab).

METHODS

We retrospectively reviewed the clinical records of R/M SCCHN patients who received cetuximab-containing chemotherapy as a first-line therapy; from these, patients receiving a weekly paclitaxel and cetuximab regimen (cohort A) and the EXTREME regimen (cohort B) were extracted. The responses, prognoses and adverse events of these two cohorts were evaluated.

RESULTS

A total of 86 patients were included (cohort A, 49; cohort B, 36). Patients with histories of platinum-based chemotherapy were more frequently given the cohort A treatment. Though the response rates were similar in the two cohorts (45% in cohort A and 51% in cohort B; p=0.83), the progression-free survival (PFS) was significantly more favorable in cohort A by the log-rank test (6.0monthsvs 5.0months; p=0.027). In the Cox-regression hazard analyses, male gender (hazard ratio [HR]=2.1, p=0.010), older age (≥ 70 yo) (HR=5.0, p=0.018), PS 0 (HR=2.2, p=0.027), no history of platinum chemotherapy (HR=3.2, p=0.003) and the presence of a tracheostomy (HR=2.3, p=0.039) were favorable factors within cohort A.

CONCLUSION

In selected R/M SCCHN patients, the combination of weekly paclitaxel and cetuximab could be the better treatment option than the EXTREME regimen.

Для цитирования: Nakano Kenji, Marshall Shoko, Taira Shinichiro, Sato Yukiko, Tomomatsu Junichi, Sasaki Toru, Shimbashi Wataru, Fukushima Hirofumi, Yonekawa Hiroyuki, Mitani Hiroki, Kawabata Kazuyoshi, Takahashi Shunji. A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.. Oral oncology. 2017. DOI: 10.1016/j.oraloncology.2017.07.022.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.